Variables | Rituximab group, n = 34 | IV-CY group, n = 20 | p value |
---|---|---|---|
Age (years) | 70.4 (8.4) | 70.9 (8.4) | 0.86 |
Gender, n (% female) | 19 (55.9%) | 10 (50.0%) | 0.78 |
Disease duration (month) | 3 (2–5) | 4 (1–7) | 0.93 |
New onset, n (%) | 34 (100.0%) | 20 (100.0%) | 1.00 |
ANCA-positive at diagnosis, n (%) | |||
Proteinase 3 ANCA | 4 (11.8%) | 0 (0.0%) | 0.28 |
Myeloperoxidase-ANCA | 26 (76.5%) | 18 (90.0%) | 0.29 |
Proteinase 3 + myeloperoxidase-ANCA | 3 (8.8%) | 1 (5.0%) | 1.00 |
ANCA-associated vasculitis type, n (%) | 0.24 | ||
MPA | 19 (55.9%) | 15 (75.0%) | |
GPA | 15 (44.1%) | 5 (25.0%) | |
BVAS | 17.4 (6.5) | 15.1 (4.6) | 0.15 |
Organ involvement, n | |||
Cutaneous involvement | 2 | 0 | 0.52 |
Mucous membranes and eyes | 3 | 2 | 1.00 |
Ear, nose, and throat | 11 | 6 | 1.00 |
Pulmonary involvement | 27 | 15 | 0.74 |
Renal involvement | 28 | 18 | 0.75 |
Neurologic involvement | 11 | 3 | 0.21 |
GC dose at base line | 56.3 (11.5) | 61.6 (16.7) | 0.17 |